AI Article Synopsis
Article Abstract
Objective: To observe the expression of matrix metalloproteinase-9 (MMP-9) and mouse double minute 2 homolog (MDM2) in the oncogenesis of lung cancer in rats and to explore their clinical value.
Methods: A total of 140 rats were selected, of which 20 were selected randomly as the control group; and the remaining 120 as the observation group. The observation group was injected with benzopyrene to establish diseases model such as tissue proliferation, abnormal proliferation and lung cancer. Detected the MMP-9 levels of lung tissue by enzyme-linked assay, detected the MDM2 levels of lung tissue by immunochemistry assay.
Results: The MMP-9 and MDM2 expression of the lung cancer group and the abnormal proliferation group were significantly higher than that in the tissue proliferation group and the control group, the difference was significant (P<0.05). And the MDM2 expression of the tissue proliferation group was significantly higher than that in the control group, the difference was significant (P<0.05). There was no significant difference in the MMP-9 expression between the tissue proliferation group and the control group (P>0.05). The MDM2 and MMP-9 expression were increased in turn in the small cell carcinoma, squamous cell carcinoma and adenocarcinoma, the difference was statistically significant (P<0.05). The MMP-9 and MDM2 expressions of stage III and stage IV lung cancer tissue in rats were significant higher than that during stage I and stage II, the difference was significant (P<0.05). There was no significantly different in the MMP-9 and MDM2 expressions between stage III and stage IV(P>0.05), and there is no significant difference of the MMP-9 and MDM2 expressions between stage I and stage II(P>0.05).
Conclusions: The expression of MMP-9 and MDM2 in lung tissue was associated with lung disease and lung cancer, both of them may be involved in the development and metastasis of lung cancer. Combined detection can be used as therapy and prognostic indicators for lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1995-7645(14)60099-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Spatial Distribution of Brain Metastasis Is Determined by the Heterogeneity of the Brain Microenvironment.
Hum Brain Mapp
December 2024
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
It is now understood that brain metastases do not occur randomly but have distinct spatial patterns depending on the origin of the cancer. According to the "seed and soil" hypothesis, the final colonization of metastatic cells is the result of their adaptation to the altered environment. To investigate the most favorable microenvironment for brain metastasis, we analyzed neuroimaging data from 177 patients with breast cancer brain metastasis and 548 patients with lung cancer brain metastasis to create a replicable probabilistic map of metastatic locations.
View Article and Find Full Text PDFVideo-assisted thoracic surgery (VATS) is a minimally invasive approach for treating early-stage non-small-cell lung cancer. Optimal trocar placement during VATS ensures comprehensive access to the thoracic cavity, provides a panoramic endoscopic view, and prevents instrument crowding. While established principles such as the Baseball Diamond Principle (BDP) and Triangle Target Principle (TTP) exist, surgeons mainly rely on experience and patient-specific anatomy for trocar placement, potentially leading to sub-optimal surgical plans that increase operative time and fatigue.
View Article and Find Full Text PDFDecoding the prognostic landscape of LUAD: the interplay between N-methyladenosine modification and immune microenvironment.
Front Immunol
December 2024
State Key Laboratory of Trauma and Chemical Poisoning, Department of Stem Cell and Regenerative Medicine, Daping Hospital, Army Medical University, Chongqing, China.
Background: To determine the role of N-methyladenosine (mA) modification in the tumor immune microenvironment (TIME), as well as their association with lung adenocarcinoma (LUAD).
Methods: Consensus clustering was performed to identify the subgroups with distinct immune or mA modification patterns using profiles from TCGA. A risk score model was constructed using least absolute shrinkage and selection operator regression and validated in two independent cohorts and LUAD tissue microarrays.
In silico neoantigen screening and HLA multimer-based validation identify immunogenic neopeptide in multifocal lung adenocarcinoma.
Front Immunol
December 2024
Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: Mutations commonly occur in cancer cells, arising neoantigen as potential targets for personalized immunotherapy of lung adenocarcinoma (LUAD). However, the substantial heterogeneity observed among individuals and distinct foci within the same patient presents significant challenges in formulating immunotherapy strategies. The aim of the work is to characterize the mutation pattern and identify neopeptides across different patients and diverse foci within the same patients with LUAD.
View Article and Find Full Text PDFLncRNA EGFR‑AS1 promotes lung cancer cell proliferation, invasion and metastasis via regulation of miR‑449a/HDAC1.
Exp Ther Med
February 2025
Department of Respiratory Medicine, Shanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Xuhui, Shanghai 200031, P.R. China.
There is increasing evidence that long non-coding (lnc)RNA EGFR-AS1 is involved in the development of numerous types of cancer, including non-small-cell lung cancer (NSCLC). The Cancer Genome Atlas (TCGA) demonstrates that EGFR-AS1 is highly expressed in NSCLC. Downregulation of EGFR-AS1 in A549 and PC9 NSCLC cells demonstrates inhibition of NSCLC proliferation, invasion and metastasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!